DreaMed Diabetes

Personalized Diabetes Treatment Optimization Solutions

Health Tech & Life Sciences
Private

Company Overview

Snapshot

Founded in March 2014 by Eran Atlas, Ido Mueller, Dr. Revital, Tadej Battelino, Thomas Danne, and Moshe Phillip, DreaMed Diabetes operates with 11–50 employees. The company has raised $16.8M across six funding rounds from five investors.

Business overview

DreaMed Diabetes develops decision-support tools for diabetes management, pioneering the first artificial pancreas technology. Its core product, endo.digital, is a cloud-based SaaS platform that provides healthcare organizations with an end-to-end diabetes care pathway solution. The platform utilizes advanced AI and analytics to transform patient data from continuous glucose monitoring, self-monitoring of blood glucose, and insulin pumps into expert-level treatment recommendations. DreaMed serves healthcare providers and patients in the digital healthcare and medical device sectors, specifically focusing on medical decision support and treatment therapeutics for both Type 1 and Type 2 diabetes.

Strategic signal

In June 2024, DreaMed Diabetes announced that Abbott's FreeStyle Libre data now integrates into its endo.digital platform. This integration is a significant development for the company, expanding the data sources available to its AI-based decision support system and enhancing its ability to provide comprehensive, personalized treatment recommendations. For investors, this signals continued product development and strategic partnerships that broaden the platform's utility and market reach within the diabetes management ecosystem.

Company Intelligence Q&A

What recent product integration did DreaMed Diabetes announce?
In June 2024, DreaMed Diabetes announced that Abbott's FreeStyle Libre data now integrates into its endo.digital platform, enhancing its data analysis capabilities for personalized diabetes treatment.
What recent case study highlighted the efficiency of DreaMed's platform?
In May 2024, a case study with Yale New Haven Health demonstrated that DreaMed's EMR-integrated deployment freed up 9 minutes per patient visit.
What was a key finding from a recent case study with Billings Clinic?
In April 2024, a case study revealed that Billings Clinic endocrinology increased CGM revenue by 60% with the endo.digital platform.
When did DreaMed Diabetes receive its fifth FDA clearance?
In October 2023, DreaMed Diabetes received its fifth FDA clearance, further validating its AI-based clinical decision support systems.

External links